AN INHALATION-TYPE THERAPEUTIC AGENT USING PULMONARY SURFACTANT FOR CORONAVIRUS TREATMENT

摘要

The present invention provides a method for preparing an inhaled coronavirus therapeutic agent so that the hydrophobic drug Zafirlukast, which is prescribed as an oral asthma treatment, is loaded into a biocompatible pulmonary surfactant containing hydrophobic lipids and can be effectively delivered to the respiratory tract. In addition, the present invention provides a method for loading zafirlukast drug in a surfactant using a relatively inexpensive pharmaceutical surfactant that can replace expensive waste surfactant. As described above, according to the method for manufacturing an inhaled coronavirus therapeutic agent using the pulmonary surfactant of the present invention, the side effects and toxicity of the therapeutic drug spread to other parts of the body are minimized, and the dosage of the therapeutic drug delivered to the treatment site is optimized. , while reducing the toxicity and side effects of the drug, it can maximize the efficacy of the treatment of coronavirus, and it has the advantage of reducing the production cost of the therapeutic agent by reducing the manufacturing process cost.